CJC-1295 and ipamorelin, explained.
Research, safety questions, and treatment context.
The form
Pharmacy catalog form
The routine
A schedule cannot be inferred from the product name.
The evidence
Human hormone findings · blend outcomes uncertain
Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- No lawful route today
No lawful compounding route today. Neither peptide was on the FDA's July 2026 docket or the review scheduled before February 2027.
- At Goodmorrow
- We offer an alternative
What it is
CJC-1295 is a long-acting version of growth hormone releasing hormone. Ipamorelin mimics ghrelin at the pituitary. Together they produce a larger growth hormone pulse than either one alone, which is why they're sold as a pair.
Both were put on the FDA's restricted list in 2023. Federal health officials said in early 2026 that they might come back, but they weren't among the peptides the FDA's advisers reviewed in July, and they aren't on the agenda for the next review either.
What the evidence shows
Both reliably raise growth hormone in short studies. Neither has been approved anywhere or tested in large, long-term human trials.
How Goodmorrow handles it
We offer sermorelin, which acts on the same pathway and is lawful to compound, and tesamorelin when belly fat is the goal.
Questions people ask
Why can other clinics still sell CJC-1295 and ipamorelin?
Some source research-grade vials, and some rely on pharmacies willing to take the risk. Neither is a lawful route today, and the patient carries the quality risk.
Sources
- Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026
- Secondary sourceCJC-1295 and Ipamorelin: Mechanism, Evidence and 2026 Regulatory Status BSR Intelligence
- Secondary sourceThe US Peptide Status Index Peptide America
Good days ahead.
Join the opening list for appointment updates.